Iovance Biotherapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $121.5 million (+80.1% year over year) and diluted EPS of -$0.05. It usually reports 36–55 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 23, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 24, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–55 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
121
+80.1%
|
-22
+75.6%
|
-0.05
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
99
+65.7%
|
-47
+57.6%
|
-0.11
+66.7%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
71
+44.8%
|
-79
+32.0%
|
-0.19
+47.2%
|
|
Feb 24, 2026
55 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
87
+17.7%
|
-72
+8.5%
|
—
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
67
+15.2%
|
-91
-9.2%
|
—
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
60
+92.7%
|
-112
-15.0%
|
-0.33
+2.9%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
49
+6798.5%
|
-116
-2.8%
|
-0.36
+14.3%
|
|
Feb 27, 2025
58 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
74
+15189.2%
|
-79
+32.5%
|
-257.71
+43.3%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IOVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1425205
- Former names
- Lion Biotechnologies, Inc. (until Jun 5, 2017); Genesis Biopharma, Inc (until Sep 23, 2013); FREIGHT MANAGEMENT CORP (until Mar 8, 2010)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.